Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could spot testicular cancer earlier

NCT ID NCT07376096

Diagnosis Sponsor: Medical University of Graz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether a liquid biopsy—a blood test that looks for tumor DNA and micro RNA—can detect and monitor testicular germ cell tumors. Researchers will collect blood samples from 200 men with stage I or metastatic testicular cancer at several time points during treatment. The goal is to see if this test can help diagnose the disease and predict outcomes, especially for patients who do not have standard tumor markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liquid biopsy (blood test for circulating tumor DNA and micro RNA)
What this could lead to
If successful, this could provide a simple blood test to detect and monitor testicular cancer, especially for patients who lack standard tumor markers.
What could go wrong
This is an early-stage study with only 200 participants, and the test may not be accurate enough to replace current methods. It is not yet proven to work in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Feb 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We aim to recruit 200 testicular germ cell tumor patients, 100 subjects with metastatic disease and 100 patients with stage I disease.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients with the age ≥ 18years with * Seminomatous or non-seminomatous germ cell tumors (extragonadal origin is allowed) * Metastatic disease * Stage I patients on active surveillance (for seminoma patients at least one risk factor, rete testis infiltration or tumor size \> 4cm, should be present) Exclusion Criteria: * Other tumors than germ cell tumors of the testis * Patients with a second malignancy within the last 5 years (except germ cell tumors) * Stage I patients who received adjuvant treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 100 metastatic patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nongerminomatous germ cell tumor seminoma testicular germ cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

100 metastatic patients 100 stage I patients

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.